Your browser doesn't support javascript.
Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
Bronstein, Yotam; Adler, Amos; Katash, Haytham; Halutz, Ora; Herishanu, Yair; Levytskyi, Katia.
  • Bronstein Y; Department of Internal Medicine D, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Adler A; Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Katash H; Department of Internal Medicine B, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Halutz O; Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Herishanu Y; Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Levytskyi K; Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Med Virol ; 94(3): 1241-1245, 2022 03.
Article in English | MEDLINE | ID: covidwho-1508794
ABSTRACT
Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunocompromised Host / Spike Glycoprotein, Coronavirus / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27445

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunocompromised Host / Spike Glycoprotein, Coronavirus / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27445